Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
322 Results for "
CDK-4
" in MedChemExpress (MCE) Product Catalog:
Products (322)
322 Results for "CDK-4" in MCE Product Catalog:
2
2 Cited Publications
2
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma [4].
2
2 Cited Publications
Synonyms: SHR-6390 hydrochloride
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma [4].
2
INK4C-IN-2 is a p18 INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED50 of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .
2
2 Cited Publications
Cat. No.: HY-N7045
CAS No.: 142796-22-3
Category:
Cyamopsis tetragonoloba (L.) Taub. Plants Flavanonols Glycine soya Flavonoids Phenols Polyphenols Compositae Extract Disease Research Fields Cancer
Target:
2
Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits CDK4 (IC50=3.9 nM), Ark5 (IC50=5 nM), PDGFRβ (IC50=26 nM), FGFR1 (IC50=26 nM), RET (IC50=9.2 nM), and FYN (IC50=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors . Narazaciclib inhibits CDK6 with an IC50 of 9.82 nM .
2
2 Cited Publications
Cat. No.: HY-162318
CAS No.: 2946670-96-6
Research Areas:
MYC degrader 1 is a MYC degrader that recruits Cereblon (CRBN), with a Kd value of 145 nM and oral activity. MYC degrader 1 specifically binds MYC and GSPT1, recruits the CRBN E3 ubiquitin ligase complex, and induces MYC degradation via the ubiquitin-proteasome pathway. MYC degrader 1 downregulates KLHL42 expression, restores pRB1 protein levels, and re-establishes the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC degrader 1 combined with Palbociclib (HY-50767) shows significant inhibition of tumor growth. MYC degrader 1 can be used in studies related to bladder cancer, prostate cancer, and breast cancer .
2
2 Cited Publications
Cat. No.: HY-162318A
MYC degrader 1 TFA is a MYC degrader that recruits Cereblon (CRBN), with a Kd value of 145 nM and oral activity. MYC degrader 1 TFA specifically binds MYC and GSPT1, recruits the CRBN E3 ubiquitin ligase complex, and induces MYC degradation via the ubiquitin-proteasome pathway. MYC degrader 1 TFA downregulates KLHL42 expression, restores pRB1 protein levels, and re-establishes the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC degrader 1 TFA combined with Palbociclib (HY-50767) shows significant inhibition of tumor growth. MYC degrader 1 TFA can be used in studies related to bladder cancer, prostate cancer, and breast cancer .
1
Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
1
1 Cited Publications
XY028-140 is a PROTAC-type degrader targeting CDK4/6, which degrades CDK4/6 by recruiting CRBN-type E3 ligase. XY028-140 can be used in CDK4/6-mediated cancer-related research .
1
1 Cited Publications
Synonyms: G1T28 hydrochloride
Trilaciclib (G1T28) hydrochloride is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
1
1 Cited Publications
NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
1
1 Cited Publications
Cat. No.: HY-P702682
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK4; Cyclin-Dependent Kinase 4; Cyclin Dependent Kinase 4; Cyclin-Dependent Kinase; PSK-J3; MCPH31; Cell Division Protein Kinase 4; CMM3; CCND1; B-Cell CLL/Lymphoma 1; Prev. PRAD1; PRAD1 Oncogene; Prev. BCL1; Parathyroid Adenomatosis 1; Prev. D11S287E; C
Species:
Human
Source:
Sf9 insect cells
1
1 Cited Publications
Cat. No.: HY-P72785
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CDKN2A; Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4); Prev. CDKN2; Multiple Tumor Suppressor 1; Prev. MLM; CDKN2A/ARF Intron 2 LncRNA; P14ARF; Alternative Reading Frame; CDK4I; Inhibitor Of CDK4 A; MTS1; MTS-1; P16; Truncated Tumor
Species:
Human
Source:
E. coli
1
1 Cited Publications
Cat. No.: HY-168660
CAS No.: 3055471-57-0
CPD-10 is a potent CCND1 and CDK4 PROTAC degrader. CPD-10 exhibits anti-proliferative effects on tumor cells and can also induce apoptosis. CPD-10 can be used for the study of breast cancer and lung cancer .
1
Gatsuciclib (AZD8421) is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9). Gatsuciclib has no significant kinase inhibition outside the CDK family. Gatsuciclib inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. Gatsuciclib can be studied in research for breast cancer and ovarian cancer .
1
1 Cited Publications
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
1
1 Cited Publications
Cat. No.: HY-N6845
CAS No.: 19275-46-8
1
1 Cited Publications
Cat. No.: HY-P80615
Synonyms: CDK4 inhibitor p16 INK4 antibody;
CDK4I antibody;
CDKN2 antibody;
CDKN2A antibody;
Cell cycle negative regulator beta antibody;
CMM2 antibody;
Cyclin dependent kinase 4 inhibitor A antibody;
Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody;
Cyclin Dependent Kinase Inhibitor 2A antibody;
Cyclin dependent kinase inhibitor 2A isoform 4 antibody;
Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody;
Cyclin dependent kinase inhibitor p16 antibody;
INK4 antibody;
INK4A antibody;
MLM antibody;
MTS1 antibody;
Multiple tumor suppressor 1 antibody;
p14 antibody;
p16 antibody;
P16INK4 antibody;
p16INK4a antibody;
p19 antibody;
p19Arf antibody;
TP16 antibody;
1
1 Cited Publications
Cat. No.: HY-P86438
Synonyms: Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p16;
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
